A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05954312

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05954312. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

Study identification

NCT ID: NCT05954312
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Enrollment: 290 participants

Conditions and interventions

Conditions

Advanced Solid Tumors

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2023 (Actual)
Primary completion: Aug 31, 2030 (Estimated)
Completion: Feb 28, 2031 (Estimated)
Last update posted: May 8, 2026

2023 – 2031

United States locations

U.S. sites: 8
U.S. states: 5
U.S. cities: 8

Facility	City	State	ZIP	Site status
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
MDACC	Houston	Texas	77030	Recruiting
NEXT Dallas	Irving	Texas	75039	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05954312, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 8, 2026 · Synced Nov 13, 2026